Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics
Published date:
05/25/2021
Excerpt:
Improved mPFS in the isatuximab group versus control group was observed both in patients with isolated 1q21 amplification (≥4 copies 1q21; 8·9 vs 2·3 months; HR, 0·55; 95% CI, 0·21–1·43;...Isatuximab–pomalidomide–dexamethasone provides a consistent benefit over pomalidomide–dexamethasone treatment in RRMM patients...